ClinicalTrials.gg
RecruitingNCT06538480Updated Dec 15, 2025

Zopa Retreatment and Vector Shedding in Adults With RRP

A Phase 4 interventional study of Zopapogene imadenovec (Zopa) in Recurrent Respiratory Papillomatosis, Papillomavirus Infection and Papillomaviridae, sponsored by Precigen, Inc. Recruiting at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-15.

Sponsored by Precigen, Inc · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Started Jul 2024; still recruiting 2 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies in Recurrent respiratory papillomatosis with a site in United States — 8 open to participants now, 9 under way, 1 of them phase 3. Recurrent respiratory papillomatosis · United States.

Planned enrollment
6th of 16
30 · median 21
Started
2024
with 1 other
Phase 4
2 of 20
1 open now
Registered
16th of 20
by date
Lead sponsor
3 of 20
Precigen, Inc

Among the 20 studies in Recurrent respiratory papillomatosis with a site in United States, this one is the 6th largest by planned enrollment of the 16 interventional ones that give a count, is one of 2 that started in 2024, is one of 2 in phase 4, and was the 16th registered.

Recurrent respiratory papillomatosis

32 studies on the registry are indexed under Recurrent respiratory papillomatosis; 9 are open to participants now.

Browse Recurrent respiratory papillomatosis studies →

Open to participants now

8 of the 20 studies in Recurrent respiratory papillomatosis with a site in United States are open now. Recruiting first, the newest first:

2 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 6 Recurrent respiratory papillomatosis studies recruiting now, 5 set no upper age limit and none stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Recurrent respiratory papillomatosis with a site in United States, or all of them as a file.
02

Study summary

This open-label study evaluates safety, vector shedding, and retreatment efficacy of Zopapogene imadenovec (Zopa) in adults with recurrent respiratory papillomatosis (RRP). Two cohorts will be enrolled (n=30): Cohort 1 to assess the magnitude and duration of adenoviral vector shedding in urine, feces, skin, and nasal tissue; Cohort 2 to assess the complete response rate following retreatment.

03

Conditions studied

  • Recurrent Respiratory Papillomatosis
  • Papillomavirus Infection
  • Papillomaviridae

Keywords

  • Human Papilloma Virus
  • laryngotracheal disease
  • papillomatous disease
  • Viral Shedding
  • Retreatment
  • Zopapogene imadenovec
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Age 18 years and older.
  • Clinical diagnosis of recurrent respiratory papillomatosis with histological confirmation of papilloma.
  • Cohort 1: Treatment-naïve with respect to Zopa.
  • Cohort 2: Received a minimum of four administrations of Zopa at 5 × 10\^11 PU per injection and require clinically indicated debulking procedures.
  • Presence of laryngotracheal papillomas accessible for endoscopic cleanout.
  • performance status 0 or 1.
  • Sexually active participants of must agree to use during treatment and for 120 days for males and 6 months for females after last dose.
  • Ability to understand and sign .

Key Exclusion Criteria:

  • Conditions or therapies that increase risk or interfere with participation per investigator judgment.
  • Systemic >10 mg prednisone equivalent or other medications within 14 days prior to dosing.
  • Other systemic RRP treatments or agents within 30 days.
  • History of heparin-induced thrombocytopenia or vaccine-induced thrombotic thrombocytopenia.
  • Active uncontrolled , , or infection.
  • Pregnant or nursing women.
  • Known allergy to any study drug component.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    Cohort 1 Vector Shedding

    Zopa administered subcutaneously at 5 × 10\^11 particle units on Day 1, Week 2, Week 6, and Week 12. Samples for vector shedding to be collected from urine, feces, skin, and nasal tissue.

    Drug: Zopapogene imadenovec (Zopa)

  • Experimental
    Cohort 2 Retreatment

    Patients with prior treatment with Zopa (5 × 10\^11 PU per injection) and require clinically indicated debulking procedure

    Drug: Zopapogene imadenovec (Zopa)

Interventions

06

What researchers measure

Primary outcomes

  1. Cohort 1 Vector shedding

    Magnitude and duration of Zopa vector shedding measured in urine, fecal, skin, and nasal tissue

    Time frame: Up to 6 weeks following last administration, with additional collections if needed until two consecutive measurements at or below limit of detection

  2. Cohort 2 Complete Response Rate

    Percentage of subjects achieving a complete response defined as no clinically indicated debulking procedures during the 12 months following completion of Zopa retreatment.

    Time frame: 12 months following last administration

Secondary outcomes

  1. Interval to First Debulking Procedure (Cohort 2)

    Determine the interval to the first debulking procedure following retreatment with Zopapogene imadenovec (Zopa).

    Time frame: 3 years following last administration

  2. Safety and Tolerability of Zopa (Cohort 1 and Cohort 2)

    Assess the safety and tolerability of Zopa in adult subjects with recurrent respiratory papillomatosis (RRP), including incidence and severity of adverse events graded per CTCAE v5.0.

    Time frame: Up to 28 days after last administration, with extended monitoring during follow-up.

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2024 (actual). Primary completion is estimated for Dec 2027, 40 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 1, 2024
First posted
Aug 5, 2024
StartActual
Jul 11, 2024
Primary completionEst.
Dec 2, 2027
CompletionEst.
Dec 2, 2028
Last update
Dec 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06538480
Lead sponsor
Precigen, Inc
Responsible party
Sponsor
First posted
Aug 5, 2024
Start date
Jul 11, 2024
Primary completion
Dec 2, 2027 (estimated)
Completion
Dec 2, 2028 (estimated)
Last update
Dec 15, 2025

Study contacts

Head of Clinical Operations
Contact
clinicaltrials@precigen.com
301-556-9900
Amy Lankford, PhD
study director · Precigen, Inc

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Zopapogene imadenovec

Start the discussion